TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CardieX ( (AU:CDX) ) has issued an update.
Cardiex Limited reported a 10% increase in revenue for FY25, driven by the launch of its new product, Pulse. The company has implemented significant cost-reduction measures, resulting in a leaner expense structure. With increased net assets and support from C2 Ventures, Cardiex is well-positioned to pursue its FY26 growth strategy, benefiting from new revenue streams and strengthened liquidity.
More about CardieX
Cardiex is a company focused on advancing medical technology in vascular health. It offers a range of products including medical and home health devices and digital solutions for conditions like hypertension and cardiovascular disease, leveraging its SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange (ASX: CDX).
Average Trading Volume: 447,789
Technical Sentiment Signal: Sell
Current Market Cap: A$16.5M
For detailed information about CDX stock, go to TipRanks’ Stock Analysis page.